Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308402877> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4308402877 abstract "<h3>Background</h3> The BAF family of chromatin remodeling complexes are critical regulators of chromatin accessibility and gene expression, and BRM and BRG1 (also known as SMARCA2 and SMARCA4), the catalytic subunits of BAF, provide the enzymatic activity required for chromatin remodeling activity. We have previously identified and characterized a series of novel dual inhibitors of the BRM/BRG1 ATPases, and FHD-286, a potent and selective BRM/BRG1 inhibitor, is currently under clinical investigation for the treatment of metastatic uveal melanoma and advanced hematological malignancies (NCT04879017 and NCT04891757). BAF chromatin remodeling complex activities are implicated in many immunologic responses, and previous studies have shown the involvement of PBAF in the regulation of antitumor immunity.<sup>1</sup> <h3>Methods</h3> Given the recent reports correlating SMARCA4 deficiency and ICI response,<sup>2</sup> we explored the combination of BRM/BRG1 ATPase inhibition and anti-PD-1 antibody in syngeneic mouse models from various lineages and with different sensitivities to checkpoint inhibition. <h3>Results</h3> The combination of FHD-286 and anti-PD-1 antibody provided synergistic efficacy and survival benefit compared to anti-PD-1 alone in A20, CT26, and the immunologically barren B16F10 melanoma model. FHD-286 increased MHCI expression on B16F10 cells, and increases in IFNγ and Th1-type chemokine CXCL10 levels were observed in immunocompetent mice following treatment, suggesting that combinatorial activity may result from effects on both the tumor and the immune system. <h3>Conclusions</h3> FHD-286 has the potential to sensitize tumor to immune-checkpoint inhibition and represents a novel combination approach for cancer immunotherapy. <h3>References</h3> Pan D, <i>et al</i>. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. <i>Science</i>. 2018; <b>359</b>:770–775. Zhou M, <i>et al</i>. Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. <i>Oncogenesis</i>. 2021; <b>10</b>:3." @default.
- W4308402877 created "2022-11-11" @default.
- W4308402877 creator A5018271642 @default.
- W4308402877 creator A5019308752 @default.
- W4308402877 creator A5024517878 @default.
- W4308402877 creator A5041831440 @default.
- W4308402877 creator A5047133226 @default.
- W4308402877 creator A5047249666 @default.
- W4308402877 creator A5077234337 @default.
- W4308402877 creator A5078970169 @default.
- W4308402877 creator A5079460736 @default.
- W4308402877 creator A5086182257 @default.
- W4308402877 creator A5088240960 @default.
- W4308402877 date "2022-11-01" @default.
- W4308402877 modified "2023-09-25" @default.
- W4308402877 title "888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models" @default.
- W4308402877 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0888" @default.
- W4308402877 hasPublicationYear "2022" @default.
- W4308402877 type Work @default.
- W4308402877 citedByCount "0" @default.
- W4308402877 crossrefType "proceedings-article" @default.
- W4308402877 hasAuthorship W4308402877A5018271642 @default.
- W4308402877 hasAuthorship W4308402877A5019308752 @default.
- W4308402877 hasAuthorship W4308402877A5024517878 @default.
- W4308402877 hasAuthorship W4308402877A5041831440 @default.
- W4308402877 hasAuthorship W4308402877A5047133226 @default.
- W4308402877 hasAuthorship W4308402877A5047249666 @default.
- W4308402877 hasAuthorship W4308402877A5077234337 @default.
- W4308402877 hasAuthorship W4308402877A5078970169 @default.
- W4308402877 hasAuthorship W4308402877A5079460736 @default.
- W4308402877 hasAuthorship W4308402877A5086182257 @default.
- W4308402877 hasAuthorship W4308402877A5088240960 @default.
- W4308402877 hasBestOaLocation W43084028771 @default.
- W4308402877 hasConcept C104317684 @default.
- W4308402877 hasConcept C159654299 @default.
- W4308402877 hasConcept C167227067 @default.
- W4308402877 hasConcept C185592680 @default.
- W4308402877 hasConcept C203014093 @default.
- W4308402877 hasConcept C502942594 @default.
- W4308402877 hasConcept C55493867 @default.
- W4308402877 hasConcept C80828422 @default.
- W4308402877 hasConcept C83640560 @default.
- W4308402877 hasConcept C86803240 @default.
- W4308402877 hasConcept C8891405 @default.
- W4308402877 hasConceptScore W4308402877C104317684 @default.
- W4308402877 hasConceptScore W4308402877C159654299 @default.
- W4308402877 hasConceptScore W4308402877C167227067 @default.
- W4308402877 hasConceptScore W4308402877C185592680 @default.
- W4308402877 hasConceptScore W4308402877C203014093 @default.
- W4308402877 hasConceptScore W4308402877C502942594 @default.
- W4308402877 hasConceptScore W4308402877C55493867 @default.
- W4308402877 hasConceptScore W4308402877C80828422 @default.
- W4308402877 hasConceptScore W4308402877C83640560 @default.
- W4308402877 hasConceptScore W4308402877C86803240 @default.
- W4308402877 hasConceptScore W4308402877C8891405 @default.
- W4308402877 hasLocation W43084028771 @default.
- W4308402877 hasOpenAccess W4308402877 @default.
- W4308402877 hasPrimaryLocation W43084028771 @default.
- W4308402877 hasRelatedWork W1745437309 @default.
- W4308402877 hasRelatedWork W1966284917 @default.
- W4308402877 hasRelatedWork W2141978478 @default.
- W4308402877 hasRelatedWork W2165585387 @default.
- W4308402877 hasRelatedWork W2810413256 @default.
- W4308402877 hasRelatedWork W2969861110 @default.
- W4308402877 hasRelatedWork W3110916976 @default.
- W4308402877 hasRelatedWork W3127099806 @default.
- W4308402877 hasRelatedWork W3207842002 @default.
- W4308402877 hasRelatedWork W93717923 @default.
- W4308402877 isParatext "false" @default.
- W4308402877 isRetracted "false" @default.
- W4308402877 workType "article" @default.